Skip to main content
. 2009 May 20;16(7):1052–1059. doi: 10.1128/CVI.00095-09

TABLE 2.

Comparison of neutralizing antibody titers using prototype DENV, ChimeriVax-DENV, and ChimeriVax-DENV parental strains in PRNT90

Specimen type (no. of samples) Specimen no. Neutralizing antibody titers in PRNT90a
Prototype DENV
ChimeriVax-DENV
ChimeriVax-DENV parental strains
DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4 DENV1 DENV2 DENV3 DENV4
DENV1 infection (15) 1 1,280 — — — 5,120 40 — — 160 — — —
2 1,280 40 — — 640 40 20 — 160 — 20 —
3 640 — — — 80 20 — — 160 — — —
4 160 — — — 320 — — — 20 — — —
5 160 — — — 160 — — — 160 — — —
6 160 — — — 80 — — — 80 — — —
7 320 — — — 2,560 40 40 20 320 — — —
8 1,280 — 40 20 320 80 80 20 640 — 40 —
9 40 — — — 40 — — — 40 — — —
10 320 — — — 640 — — — 160 — — —
11 320 — — 20 640 20 20 — 320 — 20 —
12 640 40 20 20 1,280 80 40 — 640 — 20 —
13 80 ND ND ND 160 ND ND ND 160 ND ND ND
14 40 — — — 640 20 — — 160 — — —
15 20 — — — 80 20 — — 40 — — —
DENV2 infection (12) 16 20 320 — — — 640 — — — 160 — —
17 40 160 — — — 320 — — — 80 — —
18 40 640 — — — 640 20 — — 320 — —
19 160 640 20 — 40 640 40 40 20 320 20 —
20 40 320 — — — 320 — — — 80 — —
21 — 80 — — — 160 — — — 80 — —
22 — 160 — — — 320 — — — 320 — —
23 20 320 — 20 — 320 20 — — 160 20 —
24 20 320 — — — 1,280 — — 20 160 — —
25 — 160 — — — 640 — — — 40 — —
26 — 320 — — — 1,280 — — — 320 — —
27 — 640 — — — 1,280 — — — 320 — —
DENV3 infection (3) 28 — — — — — — — — — — — —
29 — — 40 — — — 40 — — — 80 —
30 20 — 160 — 20 — 320 — — — 160 —
DENV4 infection (3) 31 — — — 1,280 — — — 160 — — — 320
32 — 20 — 320 — 20 — 160 — — — 320
33 — 40 — 5,120 — 20 — 2,560 — — — 5,120
Secondary DENV infection (3) 34 1,280 640 640 640 640 1,280 320 640 1,280 320 640 80
35 5,120 2,560 5,120 5,120 5,120 10,240 2,560 5,120 5,120 1,280 10,240 1,280
36 10,240 5,120 10,240 40,960 5,120 20,480 5,120 40,960 10,240 2,560 20,480 10,240
WNV infection (3) 37-39 — — — — — — — — — — — —
YFV vaccinated (3) 40-42 — — — — — — — — — — — —
All flavivirus negative (6) 43-48 — — — — — — — — — — — —
Positive controlsb
    DENV1 640 (5,120) (80) (160) (80) 2,560 (2,560) (80) (320) (160) 1,280 (320) (20) (40) (—)
    DENV2 (320) 1,280 (1,280) (80) (160) (160) 2,560 (2,560) (160) (80) (—) 640 (80) (—) (—)
    DENV3 (320) (160) 1,280 (1,280) (160) (320) (160) 640 (2,560) (80) (80) (40) 1,280 (320) (—)
    DENV4 (160) (80) (80) 5,120 (5,120) (160) (80) (80) 2,560 (2,560) (—) (—) (—) 1,280 (80)
Negative controlc — — — — — — — — — — — —
a

The neutralizing antibody titer is expressed as the reciprocal of the endpoint serum dilution that neutralized the challenge virus plaque count by 90%. LLOQ has a neutralizing antibody titer of 20; only positive titers (≥20) are shown. Dash = no detectable titer (<20). A neutralizing titer difference of more than fourfold between antibody to the homologous DENV serotype and antibodies to the other DENV serotypes indicates a DENV serotype-specific antibody response. The neutralizing antibody titers in parentheses are the results of the initial evaluations of the MHIAF samples using each of the four DENV serotypes as challenge viruses. These titers are shown to illustrate the level of cross-reactivity of the MHIAF samples to the other DENV serotypes. ND, not done due to insufficient sample volume.

b

MHIAF produced against a single DENV serotype.

c

Normal human control serum.